These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 14758140)

  • 1. Phase I study with dose escalation of gemcitabine and cisplatin in combination with ifosfamide (GIP) in patients with non-small-cell lung carcinoma.
    Bourgeois H; Billiart I; Chabrun V; Chieze S; Lemerre D; Germain T; Ferrand V; Meurice JC; Daban A; Tourani JM
    Am J Clin Oncol; 2004 Feb; 27(1):89-95. PubMed ID: 14758140
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-finding study of fixed dose gemcitabine and escalating doses of ifosfamide given on days 1 and 8 in patients with advanced non-small cell lung cancer.
    Baka S; Manegold C; Buchholz E; Schott-von-Römer K; Lorigan P; Nagel S; Blackhall F; Aschroft L; Thatcher N
    Lung Cancer; 2006 Aug; 53(2):165-70. PubMed ID: 16787686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Triplet chemotherapy combination with gemcitabine, cisplatin and ifosfamide in patients with advanced non-small-cell lung cancer: phase II study.
    Mohedano Mohedano N; Sánchez Rovira P; Lozano Barriuso A; Fernandez Morales M; Medina Magan B; Jaen Morago A; Porras Quintela I; Dueñas Garcia R; Fernandez Flores E; Moreno Moreno MA
    Am J Clin Oncol; 2003 Aug; 26(4):363-5. PubMed ID: 12902886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study with gemcitabine, ifosfamide and cisplatin in advanced non-small cell lung cancer.
    Chen YM; Perng RP; Whang-Peng J; Wu HW; Lin WC; Tsai CM
    Lung Cancer; 2000 Dec; 30(3):199-202. PubMed ID: 11137205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I-II study of docetaxel-ifosfamide-cisplatin (DIP) combination chemotherapy regimen in advanced nonsmall cell lung cancer.
    Kosmas C; Tsavaris NB; Makatsoris T; Onyenadum A; Vadiaka M; Stavroyianni N; Sepsas E; Dimitropoulos D; Rokana S; Kalofonos HP
    Int J Cancer; 2002 Mar; 98(1):141-7. PubMed ID: 11857398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cisplatin plus gemcitabine versus a cisplatin-based triplet versus nonplatinum sequential doublets in advanced non-small-cell lung cancer: a Spanish Lung Cancer Group phase III randomized trial.
    Alberola V; Camps C; Provencio M; Isla D; Rosell R; Vadell C; Bover I; Ruiz-Casado A; Azagra P; Jiménez U; González-Larriba JL; Diz P; Cardenal F; Artal A; Carrato A; Morales S; Sanchez JJ; de las Peñas R; Felip E; López-Vivanco G;
    J Clin Oncol; 2003 Sep; 21(17):3207-13. PubMed ID: 12947054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A dose-escalation study of irinotecan (CPT-11) in combination with gemcitabine in patients with advanced non-small cell lung cancer previously treated with a cisplatin-based front line chemotherapy.
    Kakolyris SS; Kouroussis C; Koukourakis M; Kalbakis K; Mavroudis D; Vardakis N; Georgoulias V
    Anticancer Res; 2002; 22(3):1891-6. PubMed ID: 12168889
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I dose-escalation trial of gemcitabine and cisplatin for advanced non-small-cell lung cancer: usefulness of mathematic modeling to determine maximum-tolerable dose.
    Shepherd FA; Burkes R; Cormier Y; Crump M; Feld R; Strack T; Schulz M
    J Clin Oncol; 1996 May; 14(5):1656-62. PubMed ID: 8622085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cisplatin, gemcitabine, and paclitaxel in locally advanced or metastatic non-small-cell lung cancer: a phase I-II study. Southern Italy Cooperative Oncology Group.
    Frasci G; Panza N; Comella P; Nicolella GP; Natale M; Manzione L; Bilancia D; Cioffi R; Maiorino L; De Cataldis G; Belli M; Micillo E; Mascia V; Massidda B; Lorusso V; De Lena M; Carpagnano F; Contu A; Pusceddu G; Comella G
    J Clin Oncol; 1999 Aug; 17(8):2316-25. PubMed ID: 10561293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gemcitabine, ifosfamide, and cisplatin combination (GIP) in treatment of patients with locally advanced or metastatic nonsmall cell lung cancer: results of a phase II study.
    Planchard D; Bourgeois H; Adoun M; Paitel JF; Blanc P; Genet D; Ferru A; Meurice JC; Deletage C; Tourani JM
    Am J Clin Oncol; 2006 Aug; 29(4):345-51. PubMed ID: 16891860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cisplatin, gemcitabine and vinorelbine in locally advanced or metastatic non-small-cell lung cancer: a phase I study.
    Frasci G; Panza N; Comella P; Nicolella GP; Natale M; Pacilio C; Gravina A; Caputi V; Botti G; Comella G
    Ann Oncol; 1997 Oct; 8(10):1045-8. PubMed ID: 9402180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ifosfamide, vinorelbine and gemcitabine in advanced non-small cell lung cancer. A phase I study.
    Recchia F; De Filippis S; Rosselli M; Pompili P; Guerriero G; Rea S
    Eur J Cancer; 1999 Oct; 35(10):1457-61. PubMed ID: 10673977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Final results of the Canadian phase I dose escalation trial of gemcitabine and cisplatin for advanced non-small cell lung cancer.
    Shepherd FA; Burkes RL; Cormier Y; Crump M; Feld R; Strack T; Schulz M
    Semin Oncol; 1996 Oct; 23(5 Suppl 10):48-54. PubMed ID: 8893882
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I trial of ifosfamide, mesna, and cisplatin in advanced non-small cell lung cancer. A cancer and leukemia group B study.
    Graziano SL; Herndon JE; Richards F; DiFino S; Modeas C; Duggan DB; Green MR
    Cancer; 1993 Jul; 72(1):62-8. PubMed ID: 8389667
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I study of escalating doses of oxaliplatin in combination with fixed dose gemcitabine in patients with non-small cell lung cancer.
    Bidoli P; Stani SC; Mariani L; De Candis D; Cortinovis D; Aglione S; Zilembo N; Toffolatti L; Formisano B; Bajetta E
    Lung Cancer; 2004 Feb; 43(2):203-8. PubMed ID: 14739041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined cisplatin and gemcitabine for non-small cell lung cancer: influence of scheduling on toxicity and drug delivery.
    Abratt RP; Sandler A; Crinò L; Steward WP; Shepherd FA; Green MR; Nguyen B; Peters GJ
    Semin Oncol; 1998 Aug; 25(4 Suppl 9):35-43. PubMed ID: 9728583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide+gemcitabine followed by vinorelbine and cisplatin versus vinorelbine and cisplatin followed by ifosfamide and gemcitabine in stage IIIB-IV non small cell lung carcinoma: a prospective randomized phase III trial of the Gruppo Oncologico Italia Meridionale.
    Gebbia V; Galetta D; Caruso M; Verderame F; Pezzella G; Valdesi M; Borsellino N; Pandolfo G; Durini E; Rinaldi M; Loizzi M; Gebbia N; Valenza R; Tirrito ML; Varvara F; Colucci G;
    Lung Cancer; 2003 Feb; 39(2):179-89. PubMed ID: 12581571
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of a closely spaced ifosfamide--cisplatin schedule with the addition of G-CSF in advanced non-small-cell lung cancer and malignant melanoma.
    Planting AS; de Wit R; van der Burg ME; Stoter G; Verweij J
    Ann Oncol; 1996 Dec; 7(10):1080-2. PubMed ID: 9037369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increasing-dose gemcitabine plus low-dose cisplatin in metastatic non-small cell lung cancer.
    Artal-Cortés A; Martínez-Trufero J; Herrero A; Puértolas T; Alonso V; Corral M; Ceballos C; Maurel J; Antón A
    Anticancer Drugs; 2003 Feb; 14(2):111-8. PubMed ID: 12569297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II trial of the combination of gemcitabine, ifosfamide and cisplatin in the treatment of advanced non-small cell lung cancer.
    Vadell-Nadal C; Nogué-Aliguer M; Fabregat-Mayol X; Saigí-Grau E; Gallén-Castillo M
    Lung Cancer; 2000 May; 28(2):109-15. PubMed ID: 10717328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.